Clinical trial
Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate…
NCT00003534 · Burzynski Research Institute, Other · Withdrawn
Key facts
| NCT number | NCT00003534 |
|---|---|
| Title | Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer |
| Official title | Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Adenocarcinoma of the Prostate |
| Lead sponsor | Burzynski Research Institute, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage IV Prostate Cancer |
| Intervention type | Drug |
| Interventions | Antineoplaston therapy (Atengenal + Astugenal) |
| Enrollment | 0 |
| Start date | Oct 11, 1996 |
| Primary completion | Feb 20, 1997 |
| Completion | Feb 20, 1997 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 31, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: